NCT06307431Recruiting

A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)

Name: Clinical Trial NCT06307431
Creator: Merck Sharp & Dohme LLC
Keywords: Renal Cell Carcinoma, V940, Phase 2, biological, clinical trial, Australia,Canada,Chile,Taiwan,United States of America

A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma

Merck Sharp & Dohme LLCPhase 2ClinicalTrials.govbiological

Verified

Study focus

Disease/Condition: Renal Cell Carcinoma
Drug/Device/Intervention: V940
Study type: Interventional
Intervention type: biological

Sponsor & location

Primary sponsor: Merck Sharp & Dohme LLC
Location: New Haven,New York,Macquarie University,Québec,Santiago,Santiago,Santiago,Viña del Mar,Taipei, Australia,Canada,Chile,Taiwan,United States of America

Timeline & enrollment

Phase: Phase 2
Start date: Apr 10, 2024
End date: Jun 08, 2032
Enrollment: 272 participants

Primary outcome

Disease-Free Survival (DFS)

Summary

The primary objective of the study is to compare V940 plus pembrolizumab to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS.

ICD-10 classifications

Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06307431
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06307431 through Pure Global AI's free database. This Phase 2 trial is sponsored by Merck Sharp & Dohme LLC and is currently Recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 272 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.